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Artemisinin-based combination therapy for malaria has become widely available across Africa. Populations of Plasmodium fal-
ciparum that were previously dominated by chloroquine (CQ)-resistant genotypes are now under different drug selection pres-
sures. P. malariae, P. ovale curtisi, and P. ovale wallikeri are sympatric with P. falciparum across the continent and are fre-
quently present as coinfections. The prevalence of human Plasmodium species was determined by PCR using DNA from blood
spots collected during a cross-sectional survey in northern Angola. P. falciparumwas genotyped at resistance-associated loci in
pfcrt and pfmdr1 by real-time PCR or by direct sequencing of amplicons. Of the 3,316 samples collected, 541 (16.3%) contained
Plasmodium species infections; 477 (88.2%) of these were P. falciparum alone, 6.5% were P. falciparum and P. malariae to-
gether, and 1.1% were P. vivax alone. The majority of the remainder (3.7%) harbored P. ovale curtisi or P. ovale wallikeri alone
or in combination with other species. Of 430 P. falciparum isolates genotyped for pfcrt, 61.6% carried the wild-type allele
CVMNK at codons 72 to 76, either alone or in combination with the resistant allele CVIET. No other pfcrt allele was found.Wild-
type alleles dominated at codons 86, 184, 1034, 1042, and 1246 of the pfmdr1 locus among the sequenced isolates. In contrast to
previous studies, P. falciparum in the study area comprises an approximately equal mix of genotypes associated with CQ sensi-
tivity and with CQ resistance, suggesting either lower drug pressure due to poor access to treatment in rural areas or a rapid im-
pact of the policy change away from the use of standard monotherapies.
Malaria is a major public health problem in Angola, with 3.7million cases per year reported by the National Malaria
Control Program (NMCP), two-thirds of which occur in children
under 5 (7, 49). Although incidence rates of malaria have been
decreasing due to control measures, according to the NMCP, ma-
laria remains the primary cause ofmorbidity andmortality among
children under 5 and pregnant women, accounting for 35% of the
overall infant mortality, 60% of hospital admissions in this age
group, and 25%ofmaternal deaths (7, 8, and http://www.pmi.gov
/countries/profiles/angola_profile.pdf).
Five Plasmodium species cause human malaria in Africa: P.
falciparum, P. malariae, P. vivax, P. ovale wallikeri, and P. ovale
curtisi. The relative prevalence of each species varies across the
continent, with P. falciparum being the most common and caus-
ing the most morbidity and mortality. In Angola, according to
Ministry of Health estimates, P. falciparum accounts for 92% of
infections, followed by P. vivax in about 7% of cases and P. ma-
lariae (3%) (7, 35, 49). In countries in which malaria is endemic,
mixed-species infections are common and described at various
frequencies depending on the geographic area (2, 28, 34). How-
ever, they are often underreported due to the unfamiliarity of
laboratory technicians with microscopic forms of species other
than P. falciparum and difficulty in detecting cases with low para-
sitemia (18, 19, 27, 50).
The continuous and indiscriminate use of chloroquine (CQ) as
monotherapy in the 20th century created strong selection pressure
and led to an increased prevalence of CQ-resistant (CQR) para-
sites worldwide (11). The recent introduction of artemisinin-
based combination therapy (ACT) has changed this drug pres-
sure, and the recovery of CQ-sensitive (CQS) P. falciparum
populations has been reported in Malawi, China, and Kenya (24,
26, 33, 45). However, widespread ACT use may also increase the
prevalence of ACT-tolerant phenotypes (46).
Mutations in the P. falciparum genomic region encompassing
amino acids 72 to 76 of the CQ resistance transporter gene (pfcrt)
are associated with resistance to CQ and amodiaquine (AQ) (1, 6,
21, 29, 44). The different pfcrtmutant haplotypes have a consistent
geographical distribution: the CQR haplotype CVIET is predom-
inant in southeast Asia and Africa, whereas the AQ-resistant
(AQR) haplotype SagtVMNT is predominant in Asia and South
America, and StctVMNT, from South America, is very rare in
Africa (16).The wild-type haplotype CVMNK is widespread (6,
16, 29, 38). A recent study reported the presence of the StctVMNT
haplotype of pfcrt in Angola, but this has not yet been verified by
others (15, 37). Polymorphisms in the parasite protein Pgh-1, en-
coded by pfmdr1, are thought tomodulate resistance to drugs such
as quinine, mefloquine, halofantrine, artemisinin, lumefantrine,
CQ, and AQ (1, 21, 32, 38). Mutations in this gene have some
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association with geographic areas. Considering codons 86, 184,
1034, 1042, and 1246, the pfmdr1CQR haplotype YYSND is com-
mon in Asia and Africa, whereas NFCDY has occurred more fre-
quently in CQ-resistant parasites in the Americas (16, 24, 29, 38).
In this cross-sectional study conducted in periurban and rural
northwest Angola, we evaluated drug resistance-associated haplo-
types of pfcrt and pfmdr1 among 525 P. falciparum-infected indi-
viduals, many of whom harbored additional coinfecting Plasmo-
dium species, and discuss the implications of our findings for the
treatment of malaria in the study area.
MATERIALS AND METHODS
Study area. This study was conducted within the CISA (Health Research
Center in Angola) Project’s Health andDemographic Surveillance System
(HDSS). The HDSS study area encompasses three communes (Caxito,
Mabubas, and Úcua) of the Dande municipality, Bengo Province, in
northwesternAngola. This is a largely rural area 60 kmnorth of the capital
Luanda, spanning more than 4,700 km2. The initial census, carried out
between September 2009 and February 2010, registered 60,075 inhabit-
ants in 15,643 households distributed in 69 hamlets (9). Bengo province is
considered an area inwhichmalaria ismesoendemicwith stable transmis-
sion intensity (7). The main peak of malaria occurs in the rainy season,
between November and May (8).
Sample collection. The blood samples used for this study were col-
lected between May and August of 2010 as part of a malaria baseline
prevalence survey in women and their preschool- and school-aged chil-
dren in the HDSS study area (40). Households with at least one preschool
child (0 to 5 years old) or one school-aged child (6 to 15 years old) and a
mother/caregiver (ideally from 16 to 49 years of age) were randomly se-
lected, as described by Sousa-Figueiredo et al. (40). During the survey,
finger-prick blood samples were collected and spotted onto Whatman
3MMChr filter paper and slides. Blood spots on filter paper were left to air
dry and were stored at 4°C until DNA extraction. A total of 3,316 samples
were analyzed, 2,632 from children (1,217 females and 1,146 males) and
952 from their mothers or caregivers.
Microscopy. Thick and thin blood smears were prepared on the same
slide, stained with 10% Giemsa for 15 min, and screened for malaria
parasites by two independent microscope technicians (double blinded).
Any discordance in whether or not parasites were present was resolved by
a third reader.
DNA extraction. Genomic DNA was extracted from the dried filter
papers using a QIAmp DNA minikit (Qiagen, United Kingdom) by fol-
lowing the manufacturer’s instructions. Positive-control blood spots pre-
pared from known P. falciparum-positive samples and negative-control
blood spots prepared from uninfected blood were also included and ex-
tracted in the same way as the field samples. DNA already extracted from
samples of the other species was added to each PCR as further positive
controls.
Nested PCR for RNA (small-subunit [SSU]-rRNA) amplification
and species identification. For the determination of Plasmodium species,
we performed an optimized nested PCR (39). The first PCR was per-
formed with primers specific for the Plasmodium genus: RPLU6 and
RPLU5New (the latter primer, CYTGTTGTTGCCTTAAACTTC, was
modified from the published primer, RPLU5, by the United Kingdom
Malaria Reference Laboratory, London School of Hygiene and Tropical
Medicine [LSHTM] [unpublished data]) (39). The second nested PCR
was performed in 5 separate reactions, 4 containing Plasmodium species-
specific primers as described by Snounou et al. and an additional reaction
with primers forP. ovale wallikeri, rOVAv, described byCalderaro et al. (3,
39). DNA amplification was performed in a thermocycler (Gene Amp
PCR System 9700; Applied Biosystems). PCR products were separated on
a 2% agarose gel (Invitrogen) and stained with GelRed (Biotarget).
Real-time andnestedPCR for amplification of pfcrt codons 72 to 76.
Polymorphisms at codons 72 to 76 of the pfcrt gene were successfully
determined in 430 out of 525 P. falciparum PCR-positive samples by real-
time quantitative PCR (qPCR) using dually labeled probes complemen-
tary to CVMNK (CQ sensitive; 3D7 type), CVIET (CQR; International
Standard [IS] type), and SagtVMNT (AQR; 7G8 type) haplotypes (42). To
increase sensitivity, a first-round PCRwas carried out on all samples using
primers P1 and P2 (21). The PCR product was then used in the qPCR
procedure as described by Sutherland et al. and run on a Corbett Ro-
torgene 3000 thermocycler (Corbett Lifescience, Qiagen, Germany) (42).
Unpublished primer sequences and cycling conditions are listed in Table
1. For the analysis, a threshold was set manually by reference to the ap-
propriate positive and negative controls. DNA from 3D7 (CVMNK), IS
(CVIET from NIBSC, United Kingdom), and 7G8 (SagtVMNT) clones
TABLE 1 Unpublished primers and cycling conditions
Gene and primer Sequence
Product
size (bp) Nested PCR cycling conditions
SSU-rRNA
RPLU5New 5=-CYTGTTGTTGCC TTAAAC TTC-3= 1,200 95°C for 5 min; 25 cycles of 58°C for 2 min, 72°C for
2 min, and 94°C for 1 min; 58°C for 2 min; 72°C
for 5 min
pfcrt, nested
Nest 2 forward D1 5=-TGTGCTCATGTGTTTAAACTT-3= 145 94°C for 30 s, 30 cycles of 56°C for 30 s, and 65°C
for 1 min; 65°C for 5 min; 15°C for 5 minNest 2 reverse D2 (12) 5=-CAAAACTATAGTTACCAATTTTG-3=
pfmdr1, fragment 3, seminested
Nest 1 forward MDRFR3N1 5=-GCATTTTATAATATGCATACTG-3= 234 94°C for 1 min; 30 cycles of 94°C for 30 s, 55°C for
30 s, and 68°C for 45 s; 68°C for 2 min; 15°C for
2 min
Nest 1 reverse MDRFR3R1 5=-GGATTTCATAAAGTCATCAAC-3=
Nest 2 forward MDRFR3N2 5=-GGTTTAGAAGATTATTTCTGTAA-3= 201
Nest 2 reverse MDRFR3R1 5=-GGATTTCATAAAGTCATCAAC-3=
pfmdr1, fragment 4, seminested
Nest 1 forward MDRFR4N1 5=-CAAACCAATCTGGATCTGCAGAAG-3= 194
Nest 1 reverse MDRFR4R1 5=-CAATGTTGCATCTTCTCTTCC-3=
Nest 2 forward MDRFR4N2 5=-GATCTGCAGAAGATTATACTG-3= 182
Nest 2 reverse MDRFR4R1 5=-CAATGTTGCATCTTCTCTTCC-3=
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were used as positive controls. As the qPCRwas nested in this format, only
qualitative data were obtained.
To check for the possible presence of additional genotypes, such as
StctVMNT, that may not be recognized by our three qPCR probes, all 525
samples positive for P. falciparum, including those with apparent failure
to amplify in the qPCR, were also processed using the nested PCR proto-
cols of Djimde et al. and run on 2% agarose gels (12). A selection of 42
samples was sequenced (see below).
Nested and seminested PCR for pfmdr1 amplification. To identify
pfmdr1 haplotypes, we performed nested PCR on a subset of 184 samples
for fragment 1 (codons 86 and 184) and 177 for fragments 3 (codons 1034
and 1042) and 4 (codon 1246) of the 525 P. falciparum-positive samples
corresponding to the first two plates of extractedDNA (Fig. 1). Amplicons
for sequencingwere generated by nested and seminested PCR as described
in reference 21 and in Table 1.
Sequencing protocol for pfcrt and pfmdr1. Polymorphisms in the
pfmdr1 gene were determined by direct sequencing of the amplicons re-
sulting from the nested PCR described above using a BigDye Terminator
v3.1 cycle sequencing kit in an ABI 3730 sequencer (Applied Biosystems).
Data were analyzed using Geneious 5.4.4 Pro.
To solve discrepancies between nested and real-time PCR for pfcrt, in
particular where a bandwas present in the nested PCRbut no qPCR signal
was obtained, 42 of the 51 discordant samples were sequenced on both
strands to confirm single-nucleotide polymorphisms (SNPs) at codons 72
to 76 (Fig. 1).
Statistical analysis. Database entry methods utilized in the baseline
prevalence survey have been previously described in detail by Sousa-
Figueiredo et al. (40). Plasmodium mixed infections and resistance gene
haplotype prevalences were determined through tabulations in STATA
v11.0 software.
Ethical approval.Ethical approval for the studywas obtained from the
AngolanMinistry ofHealth Ethics Committee.Written informed consent
was obtained before inclusion in the study, and antimalarial treatment
was provided when appropriate.
RESULTS
Plasmodium species identification. Of the 3,316 blood smears
analyzed after Giemsa staining, 525 samples were found to be
infected with P. falciparum (15.8%) (40). No other Plasmodium
species, either in single or mixed infections, were detected by the
microscopists.
The same 3,316 samples were screened by SSU-rRNA-based
nested PCR, with 541 samples (16.3%) detected as having a
Plasmodium infection (Table 2). Of those infected, 493 individ-
uals (91.1%) carried a single species only. The majority of the
Plasmodium infections were due to P. falciparum single infec-
tions (88.2%), whereas P. vivax single infections were seen in 6
(1.1%) of the infected samples. P. ovale curtisi, P. ovale wal-
likeri, and P. malariae single infections were observed in less
than 2% of the infected samples: 4 (0.7%), 3 (0.6%), and 3
(0.6%), respectively. The 48 mixed-species infections included
41 individuals (7.6%) infected with 2 species, 5 (0.9%) with
triple infections, and 2 (0.4%) with quadruple infections
(Table 2). The most commonly found double species infection
was the combination of P. falciparum and P. malariae, which
was observed in 35 (6.5%) individuals.
Characterization of pfcrt alleles. The 525 samples with P. fal-
ciparum (single or mixed) infections were further investigated by
qPCR to determine each pfcrt haplotype. Alleles at pfcrt codons 72
to 76 were successfully identified in 430 out of 525 samples. A
proportion of 63.5% of the samples harbored the CVIET (CQ-
resistant) haplotype, whereas 61.6%harbored the CVMNK (wild-
type) haplotype, including the ones present in mixed infections
(25.1%) (Fig. 2).Noother haplotype occurred among our isolates,
including those which failed to generate a signal in the qPCR, as
FIG 1 Sample selection process.
Malaria Drug Resistance in Angola
October 2012 Volume 56 Number 10 aac.asm.org 5273
sequencing at codons 72 to 76 in 42 samples failed to identify
SVMNT or any other alleles.
Characterization of pfmdr1 alleles. Out of 184 samples se-
quenced for fragment 1 (codons 86 and 184), 138 produced read-
able sequences. Regarding codon 86, the wild-type N86 allele was
the most prevalent (114/138; 82.6%), while 44/138 (31.9%) of the
samples carried the tyrosine mutation (Y86) associated with CQ
and AQ resistance (Fig. 2). At codon 184, the wild-type tyrosine
TABLE 2 Prevalence of Plasmodium species and mixed infections by PCR
Type of infection (n 3,316)
Presence of:
No. positive
(% of total)
% of positive
samplesP. falciparum P.malariae P. vivax
P. ovale
curtisi
P. ovale
wallikeri
P. falciparum      477 (14.4) 88.2
P.malariae      3 (0.1) 0.6
P. vivax      6 (0.2) 1.1
P. ovale curtisi      4 (0.1) 0.7
P. ovale wallikeri      3 (0.1) 0.6
P. falciparum P.malariae      35 (1.1) 6.5
P. falciparum P. ovale curtisi      2 (0.1) 0.4
P. falciparum P. ovale wallikeri      4 (0.1) 0.7
P. falciparum P. ovale curtisi
P. ovale wallikeri
     1 (0.0) 0.2
P. falciparum P.malariae
P. ovale curtisi
     2 (0.1) 0.4
P. falciparum P.malariae
P. ovale wallikeri
     2 (0.1) 0.4
P. falciparum P.malariae
P. ovale curtisi P. ovale
wallikeri
     2 (0.1) 0.4
No. positive (% of total) 525 (15.8) 44 (1.3) 6 (0.2) 11 (0.3) 12 (0.4) 541 (16.3) 100
% of positive samples 97.0 8.1 1.1 2.0 2.2 100
FIG 2 Prevalence of haplotypes of pfcrt codons 72 to 76 and pfmdr1 codons 84, 184, 1034, 1042, and 1246. The prevalence of each haplotype was calculated with
n/nt, where n is the number of positive samples and nt is the number of successfully sequenced samples. The pfmdr1 (codons 86, 184, 1034, 1042, and 1246)mixed
haplotypes NY/FSND (7 samples), N/YYSND (8 samples), and N/YY/FSND (8 samples) were removed from the analyses.
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(Y) was also themost prevalent (101/138; 73.2%), whereas 54/138
(39.1%) carried the F184 polymorphism whether alone or in
mixed infections.
Out of 177 samples sequenced for fragments 3 and 4 of pfmdr1,
126 produced readable sequences for fragment 3 (codons 1034
and 1042) and 115 produced readable sequences for fragment 4
(codon 1246). There were no mutations found at any of these
codons, as all samples were of the wild-type haplotype 1034S,
1042N, or 1246D (Fig. 2).
In samples where a single nucleotide was detected at all codons
(i.e., no mixed-haplotype infections), the most prevalent pfmdr1
haplotype at codons 86, 184, 1034, 1042, and 1246 was the wild-
type NYSND (3D7 type) allele (38/79; 48.1%), followed by the
NFSNDhaplotype (27/79; 34.2%) and then the YYSND allele (14/
79, 17.7%) (Fig. 2). The YYSNY allele, associated with AQ resis-
tance in east Africa, was not found.
DISCUSSION
The literature regarding malaria species other than Plasmodium
falciparum in Angola is limited. Here, we describe the prevalence
of the different Plasmodium species using molecular techniques.
P. falciparum was the dominant species found in almost all in-
fected individuals (96.2%) regardless of the presence of other spe-
cies. P. vivaxwas less prevalent (1.1%) than previously reported in
Angola but was more abundant than reported for the wider geo-
graphic area, where it has appeared to be almost absent (8, 10, 36).
Furthermore, we are the first to report the existence of the two P.
ovale species (P. ovale curtisi and P. ovale wallikeri) in Angola,
confirming their presence in this region of Africa (34, 43) and
providing the first documented cases of individuals simultane-
ously infected with both P. ovale species. P. malariae and P. ovale
species occurred almost exclusively in mixed infections with P.
falciparum, and together they represented almost 9% of the total
infections.
Despite being the standard method for Plasmodium detection,
we could not identifymalaria parasites other than P. falciparum by
microscopy in ourmostly asymptomatic subjects. Parasite density
of non-falciparumPlasmodium infections is usually low and there-
fore easily missed in microscopic observation, particularly in the
absence of symptoms. Likewise, in mixed infections, other species
become difficult to differentiate from a background of large num-
bers of P. falciparum parasites.
The national guidelines for malaria treatment changed from
CQ to artemether-lumefantrine (AL) in 2004, following WHO
2001 guidelines and high treatment failure rates observed in bor-
dering countries (4, 17, 23, 25, 31, 48).However, due to difficulties
in the wide-scale distribution of AL to health facilities throughout
the country, other drugs may have been used until 2007 to 2008,
when AL became broadly available (fightingmalaria.gov/technical
/acts/angola_acts.html). The heterogeneous access to drugs across
health facilities has likely led to different drug pressures, which
may have influenced the prevalence of drug-resistant and -sensi-
tive haplotypes circulating within the country. This could explain
the fact that, in this cross-sectional community study, the prev-
alence of the CQS haplotype CVMNK was high (61.6%), con-
trasting with studies conducted in 2004 and 2008 in health
facilities in the Angolan provinces of Uíge and Luanda, where a
very high prevalence of the pfcrt 76T haplotype was found (Fig.
2) (13, 30).
Alternatively, this result suggests that, as CQ was withdrawn, a
loss of the survival advantage of CQR parasites occurred in the
absence of drug pressure, leading to a resurgence in the relative
abundance of wild-type CVMNK (20, 26). A gradual decrease in
the prevalence of CQRhaplotypes has also been observed inChina
and Kenya (33, 45). Although the antimalarial activity of CQ
would likely still be poor in our study area (as the prevalence of
pfcrt codons 72 to 76 [CVIET] is close to 64%), reintroduction of
CQ as a partner drug in ACTs or in intermittent presumptive
treatment for adults (IPTa) may become possible in Angola
should the CVMNK haplotype become predominant, as occurred
in Malawi (22, 24, 26). Nevertheless, we should be aware that the
decline in rates of CQRmutations depends on geographic, epide-
miologic, and parasite genetic factors (26, 38). Additionally, effi-
cacy trials would have to be undertaken to support in vivo the
molecular findings described here.
The pfcrt SVMNThaplotype is associatedwithAQ resistance; it
is postulated to carry a lower fitness cost than the CVIET haplo-
type and to persist among the parasite population even after the
removal of drug pressure, potentially jeopardizing the effective-
ness of artesunate-AQ, which is widely used in west Africa (37,
38). Surprisingly, this haplotype, which is usually found in South
America and parts of Asia, was detected in adult samples from
Luanda in 2007 (15).Despite the proximity of Luanda to our study
site, we have not found this haplotype among our samples, sug-
gesting that AQwould still be effective in this area. Further studies
are needed to determine which provinces harbor the StctVMNT
haplotype and whether it compromises the efficacy of artesu-
nate-AQ combination therapy.
Our pfmdr1 results (82.6% of the wild-type N86 allele) differ
from those found in Luanda in 2007/2008, where Y86 was the
most prevalent, and fromUíge in 2004, where similar proportions
of Y86 and N86 were observed (Fig. 3) (13, 15, 30). There were no
mutations at codons 1034, 1042, and 1246, i.e., 100% of the hap-
lotypes were SND, in agreement with what has been reported in
other parts of west Africa, including in Angola (13, 20, 29). We
expect that the high prevalence of pfcrt CQR and high intensity of
transmission in Uíge favor the accumulation of pfmdr1 Y86 (13,
15). This suggests that parasite populations with different pfmdr1
allele frequencies exist within the country. It would be interesting
to investigate the role of endemicity on the evolution and spread
of the studied haplotypes, as Luanda, Uíge, and Bengo are areas of
low, hyper-, and mesoendemic stable transmission, respectively
(7, 8). Alternatively, access to other drugs such as AQ, known to
select strongly for the Y86 allele (44), is more likely in urban areas,
FIG 3 Drug resistance and efficacy studies in Angola.
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leading to qualitative differences in drug pressure compared to
rural districts.
Given these results, we postulate that a reversion process is also
occurring regarding pfmdr1 (codons 86 and 184), consistent with
in vitro and in vivo observations reporting amodest decrease in the
frequency of N86Y mutations in the absence of CQ pressure (20)
and the known selective advantage of the pfmdr1 haplotype NF-
SND under AL treatment (1, 14, 44). Given the limitations of
clinical diagnosis and the limited laboratory confirmation of sus-
pected cases (such that many febrile diseases are wrongly diag-
nosed as malaria), it is possible that AL is being overprescribed,
exacerbating this selection upon pfmdr1. The presence of the NF-
SND haplotype of pfmdr1 among our samples thus raises concern
and suggests that efficientmonitoring of ACT efficacy in Angola is
needed. On the other hand, it has been postulated that limited
reintroduction of CQ, along with the use of AQ in combination
therapy, could help to prevent resistance to ACTs, as both CQ and
AQ have well-described antagonistic interactions with artemis-
inins in vitro and in vivo (5, 21, 41, 46).
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